论文部分内容阅读
目的综述拉米夫定在妊娠合并慢性乙型肝炎患者中的应用及安全性研究。方法检索近年来国内外相关文献资料并进行总结,对妊娠合并慢性乙型肝炎的患者使用拉米夫定的临床疗效、安全性,进行分析和讨论。结果研究显示,拉米夫定可以显著降低孕产妇慢性乙型肝炎病毒DNA含量,改善其肝功能,减少母婴传播风险,且不良反应较少,应用较为安全。结论拉米夫定是目前妊娠合并慢性乙型肝炎患者的主要治疗药物,可以达到抑制病毒复制,降低婴儿宫内感染,提高母婴传播阻断率的目的,为了尽量减少胎儿发育成熟前对可能危害药物的接触,拉米夫定不能盲目应用,应权衡利弊,选择恰当用药时机。
Objective To summarize the application and safety of lamivudine in patients with pregnancy complicated with chronic hepatitis B. Methods The related literatures at home and abroad in recent years were retrieved and summarized. The clinical efficacy and safety of lamivudine in patients with pregnancy complicated with chronic hepatitis B were analyzed and discussed. Results of the study showed that lamivudine can significantly reduce maternal chronic hepatitis B virus DNA content, improve liver function, reduce the risk of mother-to-child transmission, and adverse reactions less safe to use. Conclusions Lamivudine is currently the main therapeutic drug for patients with chronic hepatitis B during pregnancy, and can achieve the purpose of inhibiting viral replication, reducing intrauterine infection in infants and improving the rate of mother-to-infant transmission. In order to minimize the possibility of fetal development before maturity Endanger the exposure of drugs, lamivudine can not be blindly applied, should weigh the pros and cons, choose the appropriate medication.